Institutional members access full text with Ovid®

18F-Fluoride PET/CT Allows Detection of Hyperostosis and Osseous Involvement in Meningioma: Initial Experience

Tateishi, Ukihide MD*; Tateishi, Kensuke MD; Shizukuishi, Kazuya MD*; Shishikura, Ayako MD*; Murata, Hidetoshi MD; Inoue, Tomio MD*; Kawahara, Nobutaka MD

doi: 10.1097/RLU.0b013e318279fd79
Original Articles

Purpose: The present study was conducted to assess the diagnostic performance of 18F-fluoride PET/CT in evaluating hyperostosis and osseous involvement in patients with meningioma.

Patients and Methods: Thirty-four patients with meningioma (mean age, 61 years) underwent 18F-fluoride PET/CT before surgery. In 24 patients (71%), 18F-FDG PET/CT was also given before surgery, and the results were compared. The images were reviewed by 2 board-certified nuclear medicine specialists who were unaware of any clinical information and a consensus was reached. Uptake patterns and measurements of tracers were compared with pathological findings from resected specimens, with hyperostosis and osseous involvement as the reference standard.

Results: There were 27 grade I tumors (79%) and 7 grade II tumors (21%). The primary tumor focus was identified in each patient using both 18F-fluoroide PET/CT and 18F-FDG PET/CT, but there were no significant correlations in the degree of uptake between the 2 tracers. The SUVmax, SUVmax corrected for lean body mass (SULmax), and tumor metabolic volume (TMV) for 18F-fluoride and 18F-FDG were greater in grade II tumors than in grade I tumors. Hyperostosis and osseous involvement was identified in 12 tumors (38%). The SUVmax, SULmax, and TMV of tumors visualized with 18F-fluoride PET/CT were greater in tumors with hyperostosis and osseous involvement than in those without (P = 0.005, P = 0.003, and P = 0.006, respectively). In contrast, the SUVmax, SULmax, and TMV of tumors visualized with 18F-FDG PET/CT were similar regardless of hyperostosis or osseous involvement.

Conclusions: 18F-fluoride PET/CT may improve detection of hyperostosis and osseous involvement in patients with meningioma.

From the Departments of *Radiology, and †Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

Received for publication June 4, 2012; revision accepted September 27, 2012.

Supported in part by the National Cancer Center Research and Development Fund 23-A-25.

Conflicts of interest and sources of funding: none declared.

Reprints: Ukihide Tateishi, MD, Department of Radiology, Yokohama City University Graduate School of Medicine, 3–9, Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan. E-mail: utateish@yokohama-cu.ac.jp.

© 2013 by Lippincott Williams & Wilkins